PAVmed Inc. - 8-K Filing

PAVmed reports Q3 2026 preliminary results with $1.2M revenue from Lucid Diagnostics and $8.9M in cash and equivalents. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 13, 2026, 13:05 UTC

Tickers: $PAVM

Read the full article at SEC EDGAR

Part of the story IMMUNIC, INC. - 8-K Filing (2 articles)

More Regulatory news

Transglobal Management Group, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:11 UTC
REVVITY, INC. - 8-K Filing SEC EDGAR · November 13, 2026, 13:09 UTC
Owlet, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:05 UTC
Benitec Biopharma Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:02 UTC
AUTOLIV INC - 8-K Filing SEC EDGAR · November 13, 2026, 13:00 UTC
IMMUNIC, INC. - 8-K Filing SEC EDGAR · November 13, 2026, 13:00 UTC
Aveanna Healthcare Holdings, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:00 UTC
Edible Garden AG Inc - 8-K Filing SEC EDGAR · November 13, 2026, 13:00 UTC
AIM ImmunoTech Inc. - 4 Filing SEC EDGAR · November 13, 2026, 13:00 UTC
Verrica Pharmaceuticals Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 12:53 UTC